Michael Kim, MD
Interventional Cardiology · Greeley, CONPI 1386677144
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Edwards Lifesciences at 40.5% of the total.
Across 223 payments — averaging $108.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$10K
- Siemens Medical Solutions USA, Inc.$6K
- Abbott$4K
- Boston Scientific$2K
- Johnson & Johnson$294
- E.r. Squibb & Sons, L.L.C.$207
- plus $1K from 23 others
Across 14 payments — averaging $3817.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$53K
What the payments were for
- Consulting fees$4,53019%
- Speaking & faculty fees$6,62527%
- Travel & lodging$3,89616%
- Food & beverage$9,13138%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 58 | $9,794 |
| Siemens Medical Solutions USA, Inc. | 6 | $6,284 |
| Abbott | 64 | $4,319 |
| Boston Scientific | 19 | $1,918 |
| Johnson & Johnson | 7 | $294 |
| E.r. Squibb & Sons, L.L.C. | 11 | $207 |
| Novartis | 12 | $200 |
| Amgen | 9 | $190 |
| Philips North America LLC | 3 | $160 |
| Pfizer | 6 | $116 |
| Medtronic | 1 | $115 |
| Inspire Medical Systems, Inc. | 2 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $61 |
| Boehringer Ingelheim | 3 | $53 |
| Bridgebio Pharma, Inc. | 2 | $52 |
| Abiomed | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Merck | 1 | $19 |
| Shockwave Medical, Inc | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Heartflow, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$5,134
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,203
- GENERAL - THERAPIES$1,125
- TRICLIP$785
- MitraClip$711
- Mitra Clip system$359
- MitraClip System$255
- SAPIEN 3 Ultra RESILIA$218
- GENERAL - STRUCTURAL HEART$215
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$155
- INSPIRIS RESILIA aortic valve$151
- WATCHMAN FLX$142
- NAVITOR$141
- CardioMEMS HF System$125
- XARELTO$124
- Artis pheno$118
- PORTICO$117
- ONYX FRONTIER$115
- SC2000$110
- (P84) IGT Devices Systems$101
How this compares
$24,182 in reported general payments places this provider in the 70th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $218,537 |
| XareltoRivaroxaban | 38 | $53,199 |
| EntrestoSacubitril/Valsartan | 25 | $35,575 |
| Repatha SureclickEvolocumab | 28 | $34,974 |
| BrilintaTicagrelor | 15 | $9,825 |
| Metoprolol Succinate | 219 | $2,555 |
| Atorvastatin Calcium | 175 | $1,491 |
| Rosuvastatin Calcium | 155 | $1,420 |
| Losartan Potassium | 137 | $1,266 |
| Carvedilol | 156 | $1,120 |
| Flecainide Acetate | 22 | $854 |
| Amlodipine Besylate | 124 | $676 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $638 |
| Spironolactone | 73 | $637 |
| ClopidogrelClopidogrel Bisulfate | 70 | $622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $218,537166 claims |
| Johnson & JohnsonXarelto | $294 | $53,19938 claims |
| NovartisEntresto | $200 | $35,57525 claims |
| AstraZenecaBrilinta | $14 | $9,82515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Greeley
- Mark TuttleGreeley$40K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.